ClinicalTrials.gg
CompletedNCT04543383Updated Aug 15, 2025

A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

A Phase 1 interventional study of Milvexian and 4-Factor Prothrombin Complex Concentrate (4F-PCC) in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
All
01

Study summary

The primary purpose of this study is to evaluate the reversal of the anticoagulant effects of milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa (rFVIIa) in healthy participants as measured by changes from baselines of the coagulation testing parameters (activated partial thromboplastin time [aPTT] and thrombin generation assay [TGA]).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy on the basis of medical history, physical examination, vital signs, (ECG), and laboratory test results, including serum chemistry, lipid profiles (low-density lipoprotein [LDL], high-density lipoprotein [HDL], apolipoprotein B and lipoprotein a), levels of protein C, protein S and antithrombin, fibrinogen, factors VIIIc, IXc, Xc, XIc and blood coagulation ( [aPTT], prothrombin time [PT]) measured at local laboratory, hematology and urinalysis performed at screening. If abnormalities or deviations from normal are observed, they must be of no clinical significance in the opinion of the investigator
  • Before randomization, a woman must either be: Not of defined as: -A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level greater than (>) 40 International Units Per Liter (IU/L) or milli-international units per milliliter (mIU/mL) in the postmenopausal range may be used to confirm a postmenopausal state in women, however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient; Permanently sterile- Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Of childbearing potential, a woman must have an intrauterine device without estrogen- and or progestogen-containing system, or have vasectomized partner or practice sexual abstinence, agrees to remain on the above highly effective method throughout the study and for at least 90 days after the last dose of study intervention
  • A male participant must wear a condom when engaging in any activity with a woman of childbearing potential during the study and for the duration of treatment with milvexian plus 5 half-lives of the study intervention for a total of 94 days after the completion of treatment. Male participants should also be advised of the benefit for a female partner to use a highly effective method of contraception because condom may break or leak
  • If a woman, must have a negative highly sensitive serum (Beta-human chorionic gonadotropin [Beta-hCG]) pregnancy test at screening and urine (Beta-hCG) pregnancy test on Day -1 of each study period (Part 1) or on Day -1 of Period 1 (Part 2)
  • Women must have no history of excessive menstrual bleeding or hemorrhage following pregnancy delivery
  • A male participant must agree not to donate sperm for the purpose of reproduction during the study and for 94 days after receiving the last dose of study intervention
  • (weight [kilogram {kg}/height\^2 [meter {m\^2}]) more than equal to 18.0 and less than equal to 29.9 kg/m\^2 body weight not less than 50 kg and not more than 100 kg.

Exclusion criteria

Exclusion Criteria:

  • History or family history of any known illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study intervention to the participant or that could prevent, limit or confound the protocol specified assessments. This may include but is not limited to any known bleeding or clotting disorder, cardiolipin antibody and anti-beta2-glycoprotein I, abnormal levels of fibrinogen, factors VIIIc, IXc, Xc, XIc, inherited or acquired thrombophilia, bleeding diathesis or coagulopathy, excessive bruising, bleeding from nose or gums or known disorders with increased bleeding risk, serious bleeding including gastrointestinal bleeding requiring hospitalization, intracranial bleeding of any type, or uncontrollable postoperative bleeding, a history of arterial or venous thrombosis, phlebitis, inherited or acquired thrombophilia, known family history of unexplained thrombotic disorders, known intracranial or intraabdominal tumor, hemorrhage, or aneurysm, liver or renal dysfunction, cardiac, vascular disorders, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, neoplastic abnormalities, or metabolic disturbances, or poor venous access
  • History of drug or alcohol abuse according to criteria within 1 year before screening or positive test result(s) for alcohol and/or drugs of abuse (such as hallucinogens (lysergic acid diethylamide [LSD]), barbiturates, opiates, opioids, cocaine, cannabinoids, amphetamines, and benzodiazepines) at screening and/or on Day -1 of Period 1
  • Have laboratory values at screening or Day -1 of Period 1 above or below limits of normal that in the investigator's judgment may affect the safety of the participants
  • Any of the following laboratory results outside of the ranges specified below at screening or on Day -1 of Period 1, confirmed by repeat: or hematocrit \< lower limit of normal, count less than (\<) lower limit of normal, , or PT > (ULN), LDL, HDL, apolipoprotein B, or lipoprotein a, outside the normal reference ranges, Factor II gene mutation or Factor V Leiden mutation assessed by polymerase chain reaction (PCR) tests, positive for Lupus Anticoagulants (LA screen, confirm and Silica Clotting Time [SCT]), cardiolipin antibody and anti-beta2-glycoprotein I, abnormal levels of protein C, protein S, antithrombin, fibrinogen, factors VIIIc, IXc, Xc, XIc
  • Any of the following on 12-lead based on an average of triplicate measurements at screening or Day -1 of Period 1: PR greater than or equal to (>=) 210 millisecond (msec), QRS >=120 msec, >=450 msec for male and >=470 msec for female, Heart Rate (HR) >= 100 beats per minute (bpm)
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) and known allergy to the study interventions or any of the of the formulations. History of allergy to or unwillingness to consume any component of high-fat breakfast menu to be provided in this study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Part 1

    Participants will receive two oral doses of milvexian (on Days 1 to 3), one in the morning and one in the evening. On Day 4, participants will only receive the morning dose of milvexian. On Day 4, four hours after the morning dosing of milvexian, each participant will receive an intravenous (IV) infusion of 4-Factor Prothrombin Complex Concentrate (4F-PCC) or matching placebo as per the treatment sequence AB and BA; in treatment period 1 and treatment period 2 where Treatment A=Dose 2 of milvexian + Dose 1 of 4F-PCC; Treatment B=Dose 2 milvexian + Placebo. A washout period of 14 days to 21 days will be maintained between each treatment period 1 and 2.

    Drug: Milvexian · Biological: 4-Factor Prothrombin Complex Concentrate (4F-PCC) · Biological: Placebo matching to 4F-PCC

  • Experimental
    Part 2 (Group 1)

    Participants will receive an oral dose of milvexian in morning in fed state on Day 1 and IV injection of Recombinant Human Factor VIIa (rFVIIa) or placebo matching to rFVIIa on Day 1 after 4 hours post morning milvexian dose in the following treatment sequence: DEF1, EF1D, F1DE, EDF1, F1ED and DF1E; in treatment period 1, treatment period 2 and treatment period 3 respectively where Treatment D=Dose 1 of milvexian +Dose 1 of rFVIIa; Treatment E=Dose 3 of milvexian+Dose 1 of rFVIIa; Treatment F1=Dose 3 of milvexian+Placebo; Treatment F2=Dose 1 of milvexian+Placebo. A washout period of 4 days will be maintained between each treatment period 1, 2 and 3.

    Drug: Milvexian · Biological: Recombinant Human Factor VIIa (rFVIIa) · Biological: Placebo matching to rFVIIa

  • Experimental
    Part 2 (Group 2)

    Participants will receive an oral dose of milvexian in morning in fed state on Day 1 and IV injection of rFVIIa or placebo matching to rFVIIa on Day 1 after 4 hours post morning milvexian dose in the following treatment sequence: DEF2, EF2D, F2DE, EDF2, F2ED and DF2E; in treatment period 1, treatment period 2 and treatment period 3 respectively where Treatment D=Dose 1 of milvexian+Dose 1 of rFVIIa; Treatment E=Dose 3 of milvexian+Dose 1 of rFVIIa; Treatment F1=Dose 3 of milvexian+Placebo; Treatment F2=Dose 1 of milvexian+Placebo. A washout period of 4 days will be maintained between each treatment period 1, 2 and 3.

    Drug: Milvexian · Biological: Recombinant Human Factor VIIa (rFVIIa) · Biological: Placebo matching to rFVIIa

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Change from Baseline in Activated Partial Thromboplastin Time (aPTT)

    The aPTT measures the time it takes plasma to clot when exposed to substances that activate the contact factors, which assesses the intrinsic and common pathways of coagulation.

    Time frame: Baseline, Day 4

  2. Part 2: Change from Baseline in aPTT

    The aPTT measures the time it takes plasma to clot when exposed to substances that activate the contact factors, which assesses the intrinsic and common pathways of coagulation.

    Time frame: Baseline, Day 1

  3. Part 1: Change from Baseline in Endogenous Thrombin Potential (ETP) (Thrombin Generation Assay [TGA] Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the ETP (TGA parameter). The ETP assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro and anti-coagulant forces in plasma.

    Time frame: Baseline, Day 4

  4. Part 1: Change from Baseline in Lag Time (TGA Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the lag time (TGA parameter). The lag time is defined as the time needed until thrombin is generated.

    Time frame: Baseline, Day 4

  5. Part 1: Change from Baseline in Peak Thrombin (TGA Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the peak thrombin (TGA parameter). The peak thrombin is defined as the maximal effect on thrombin generation.

    Time frame: Baseline, Day 4

  6. Part 1: Change from Baseline in Time to Peak Thrombin (TGA Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the time to peak thrombin (TGA parameter). The time to peak thrombin is defined as the time required to reach maximal effect on thrombin generation.

    Time frame: Baseline, Day 4

  7. Part 2: Change from Baseline in ETP (TGA Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the ETP (TGA parameter). The ETP assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro and anti-coagulant forces in plasma.

    Time frame: Baseline, Day 1

  8. Part 2: Change from Baseline in Lag Time (TGA Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the lag time (TGA parameter). The lag time is defined as the time needed until thrombin is generated.

    Time frame: Baseline, Day 1

  9. Part 2: Change from Baseline in Peak Thrombin (TGA Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the peak thrombin (TGA parameter). The peak thrombin is defined as the maximal effect on thrombin generation.

    Time frame: Baseline, Day 1

  10. Part 2: Change from Baseline in Time to Peak Thrombin (TGA Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the time to peak thrombin (TGA parameter). The time to peak thrombin is defined as the time required to reach maximal effect on thrombin generation.

    Time frame: Baseline, Day 1

Secondary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAE) as a Measure of Safety and Tolerability

    Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) with onset or worsening on or after date of first dose of study treatment.

    Time frame: Part 1: Up to 74 Days; Part 2: Up to 25 Days

  2. Number of Participants with TEAEs of interest

    Number of participants with TEAEs of interest will be reported. TEAEs associated with the following situations are considered as TEAEs of interest: bleeding, thromboembolic events (TEs) and liver injury.

    Time frame: Part 1: Up to 74 Days; Part 2: Up to 25 Days

  3. Parts 1 and 2: Change From Baseline in Pulse Rate

    Changes from baseline in pulse rate will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  4. Parts 1 and 2: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Changes from baseline in SBP and DBP will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  5. Parts 1 and 2: Change From Baseline in QTc Interval

    Change from baseline in QT interval corrected for heart rate (QTc interval) using Fridericia method will be measured by ECG.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  6. Parts 1 and 2: Change from Baseline in Heart Rate (HR)

    Change from baseline in HR will be measured by ECG.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  7. Parts 1 and 2: Change from Baseline in QRS Interval

    Change from baseline in QRS interval will be measured by ECG

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  8. Parts 1 and 2: Change from Baseline in PR Interval

    Change from baseline in PR interval will be measured by ECG.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  9. Parts 1 and 2: Change From Baseline in QT Interval

    Change from baseline in QT interval will be measured by ECG.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  10. Parts 1 and 2: Change From Baseline in Hematology Parameter: Platelet Count

    Change from baseline in hematology parameter (platelet count) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  11. Parts 1 and 2: Change From Baseline in Hematology Parameter: Red Blood Cell (RBC) count

    Change from baseline in hematology parameter (RBC count \[Unit: Cells per liter\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  12. Parts 1 and 2: Change From Baseline in Hematology Parameter: Hemoglobin (Hb)

    Change from baseline in hematology parameter (Hb \[Grams per deciliter\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  13. Parts 1 and 2: Change From Baseline in Hematology Parameter: Hematocrit

    Change from baseline in hematology parameter (Hematocrit) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  14. Parts 1 and 2: Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)

    Change from baseline in hematology parameter (MCV \[Femtoliter\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  15. Parts 1 and 2: Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)

    Change from baseline in hematology parameter (MCH \[Picogram\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  16. Parts 1 and 2: Change From Baseline in Hematology Parameter: Percentage of Reticulocytes

    Change from baseline in hematology parameter (Percentage of reticulocytes) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  17. Parts 1 and 2: Change From Baseline in Hematology Parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils

    Change from baseline in hematology parameters (Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils \[Unit: Giga cells per liter\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  18. Parts 1 and 2: Change From Baseline in Coagulation Parameter: Activated Partial Thromboplastin Time (aPTT) and Prothrombin Time (PT)

    Change from baseline in coagulation parameter (aPTT and PT \[Unit: Seconds\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  19. Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides

    Change from baseline in serum chemistry parameters (Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Sodium, Blood urea nitrogen \[BUN\], Cholesterol, High density Lipoprotein \[HDL\], Low density lipoprotein \[LDL\], Triglycerides \[Unit: Millimole per Liter\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  20. Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: ALT, AST, GGT, LDH, Alkaline phosphatase, CPK

    Change from baseline in serum chemistry parameters (Alanine Aminotransferase \[ALT\], Aspartate Aminotransferase \[AST\], Gamma-glutamyl transferase \[GGT\], Lactic acid dehydrogenase \[LDH\], Alkaline phosphatase, Creatine phosphokinase \[CPK\] \[Unit: International units per Liter\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  21. Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Amylase

    Change from baseline in serum chemistry parameters (Amylase \[Unit: Units per liter\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  22. Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Lipase

    Change from baseline in serum chemistry parameters (Lipase \[Unit: Units per liter\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  23. Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Total Bilirubin, Creatinine and Uric Acid

    Change from baseline in serum chemistry parameters (Total bilirubin, Creatinine and Uric acid \[Unit: Micromoles per Liter\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  24. Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Total Protein and Albumin

    Change from baseline in serum chemistry parameters (Total protein and Albumin \[Unit: Gram per Liter\]) will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  25. Parts 1 and 2: Change From Baseline in Urinalysis Parameter: Specific Gravity

    Change from baseline in urinalysis parameter (Specific gravity) tests will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  26. Parts 1 and 2: Change From Baseline in Urinalysis Parameter: pH

    Change from baseline in urinalysis parameter (pH) tests will be assessed.

    Time frame: Part 1: Up to 77 Days; Part 2: Up to 59 Days

  27. Part 1: Mean Trough Plasma Concentration of Milvexian at Steady State (Ctrough)

    Mean trough plasma concentration of milvexian at steady state will be reported.

    Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose

  28. Part 1 and Part 2: Maximum Observed Analyte Concentration (Cmax) of Milvexian

    Cmax is the maximum observed analyte concentration.

    Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose; Part 2: 0.25, 2, 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  29. Part 1 and Part 2: Time to Reach Maximum Plasma Concentration (Tmax) of milvexian

    Tmax is defined as actual sampling time to reach the maximum observed analyte concentration.

    Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose; Part 2: 0.25, 2, 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  30. Parts 1 and Part 2: Elimination Half-Life (t1/2) of Milvexian

    t1/2 elimination half-life means time measured for the plasma concentration to decrease by 1 half to its original concentration of milvexian.

    Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose; Part 2: 0.25, 2, 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  31. Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Dosing Interval (AUC [0-t]) of Milvexian

    Area under the plasma concentration versus time curve from time zero to dosing interval of milvexian.

    Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose

  32. Part 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of Milvexian

    Area under the plasma concentration versus time curve from time zero to infinity with extrapolation of the terminal phase of milvexian.

    Time frame: Part 2: 0.25, 2, 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  33. Part 1 and Part 2: Area Under Plasma Concentration From Time Zero to the Last Quantifiable Concentration (AUC [0-last]) of Milvexian

    Area under the plasma concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration of milvexian will be assessed.

    Time frame: Part 1: Predose, 2, 4, 4.75, 5, 6, 8, 12, 24, 48, and 72 hours Postdose; Part 2: 0.25, 2, 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  34. Part 2: Maximum Observed Analyte Concentration (Cmax) of rFVIIa

    Cmax is the maximum observed analyte concentration.

    Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  35. Part 2: Time to Reach Maximum Plasma Concentration (Tmax) of rFVIIa

    Tmax is defined as actual sampling time to reach the maximum observed analyte concentration.

    Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  36. Part 2: Elimination Half-Life (t1/2) of rFVIIa

    t1/2 elimination half-life means time measured for the plasma concentration to decrease by 1 half to its original concentration of rFVIIa.

    Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  37. Part 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of rFVIIa

    Area under the plasma concentration versus time curve from time zero to infinity with extrapolation of the terminal phase of rFVIIa.

    Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  38. Part 2: Area Under Plasma Concentration From Time Zero to the Last Quantifiable Concentration (AUC [0-last]) of rFVIIa

    Area under the plasma concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration of rFVIIa will be assessed.

    Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  39. Part 2: Systemic Clearance (CL) of rFVIIa

    CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose will be estimated by dividing the total administered dose by the area under the plasma concentration-time curve from time zero to infinite time (AUC \[0-infinity\]).

    Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  40. Part 2: Volume of distribution (Vz) of rFVIIa

    The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.

    Time frame: Part 2: 4, 4.25, 4.5, 5, 6, 8, 12, 24 hours Postdose

  41. Part 1 and Part 2: Change from Baseline in aPTT

    Change from baseline in aPTT will be reported.

    Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2

  42. Part 1 and Part 2: Change from Baseline in ETP (TGA Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the ETP (TGA parameter). The ETP assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro and anti-coagulant forces in plasma.

    Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2

  43. Part 1 and Part 2: Change from Baseline in Lag Time (TGA Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the lag time (TGA parameter). The lag time is defined as the time needed until thrombin is generated.

    Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2

  44. Part 1 and Part 2: Change from Baseline in Peak Thrombin (TGA Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the peak thrombin (TGA parameter). The peak thrombin is defined as the maximal effect on thrombin generation.

    Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2

  45. Part 1 and Part 2: Change from Baseline in Time to Peak Thrombin (TGA Parameter)

    The TGA measures the thrombin generation that is indicative of an overall coagulating capacity. A calibrated automated thrombography is used to monitor the concentration of thrombin in clotting plasma with a fluorogenic substrate. The data derived from the thrombography can be used to determine the time to peak thrombin (TGA parameter). The time to peak thrombin is defined as the time required to reach maximal effect on thrombin generation.

    Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2

  46. Percent Change from Baselines in aPTT

    Percent change from baseline in aPTT will be reported.

    Time frame: Part 1: Baseline, Day 1, Day 4, Day 5, Day 6 and Day 7; Part 2: Baseline, Day 1 and Day 2

07

Study locations

1 site
  • PRA Health Sciences
    Groningen, NZ 9728, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Jun 2023, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2020
First posted
Sep 10, 2020
StartActual
Jul 27, 2020
Primary completionActual
Jun 7, 2023
CompletionActual
Jun 9, 2023
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04543383
Responsible party
Sponsor
First posted
Sep 10, 2020
Start date
Jul 27, 2020
Primary completion
Jun 7, 2023
Completion
Jun 9, 2023
Last update
Aug 15, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Four-factor Prothrombin Complex Concentrate

Start the discussion